Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00984659 · ClinicalTrials.gov registry record · Phase 4
Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 366
- Enrollment target
NCT00984659: Completed Phase 4 study, sponsored by GlaxoSmithKline.
NCT00984659 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 366 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00984659, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 366 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate a new questionnaire to capture the patient experience of COPD. The information collected will be used to validate the Shortness of Breath with Daily Activities Questionnaire.
Primary Outcome
Cronbach's alpha (CA) is a measure of the IC of the 13-item SOBDA questionnaire (completed via electronic diary by a sample of participants). It is the ratio of the variance (var.) of the sum of the individual scores and the var. of the total score. The var. of the sum of a group of independent variables is the sum of their var.; thus, if the variables are positively correlated, the var. of the sum will be increased. If the items making up the score are identical and so perfectly correlated, CA=
Interventions
- DRUG Placebo
- DRUG Salmeterol
- DRUG Fluticasone propionate/salmeterol combination product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2009-10-29 |
| Est. Completion | 2010-07-01 |
| Phase | Phase 4 |
What the finished NCT00984659 record still lists
NCT00984659 is an interventional study that assigns participants to a tested intervention. The registered 366 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00984659 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00984659 about?
NCT00984659 is a clinical study titled "Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease". The purpose of this study is to evaluate a new questionnaire to capture the patient experience of COPD. The information collected will be used to validate the Shortness of Breath with Daily Activities Questionnaire.
What is the current status of trial NCT00984659?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 366 participants. The study started on 2009-10-29. Estimated completion is 2010-07-01.
What interventions are being tested in trial NCT00984659?
The interventions under investigation include: Placebo (DRUG), Salmeterol (DRUG), Fluticasone propionate/salmeterol combination product (DRUG).
Who is sponsoring clinical trial NCT00984659?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00984659's enrollment target sits among peer trials
366 225th of 2000 higher than 1,776 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05083481 · 366 participants · Phase 1
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
- NCT05429632 · 366 participants · Phase 3
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- NCT06979453 · 366 participants · Phase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI